Valiant Laboratories Ltd
NSE: VALIANTLAB BSE: 543998
₹125.08
(0.91%)
Sun, 11 Oct 2026, 11:14 pm
Market Cap (in Cr)663.16
PE Ratio42.40
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KValiant Laboratories Balance Sheet
| Particulars | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Interest expense on debt | -17.84M | -730.00K | -2.54M | -778.00K | -1.75M |
| Pretax equity in earnings | 0 | 0 | 0 | 0 | 0 |
| Equity in earnings | 0 | 0 | 0 | 0 | 0 |
| Total assets | 1.06B | 1.82B | 2.13B | 3.43B | 4.01B |
| Total current assets | 858.90M | 1.57B | 1.51B | 2.26B | 1.93B |
| Cash and short term investments | 189.37M | 205.33M | 353.60M | 1.44B | 759.91M |
| Cash & equivalents | 39.37M | 1.31M | 12.62M | 117.18M | 49.16M |
| Short term investments | 150.00M | 204.02M | 340.99M | 1.32B | 710.75M |
| Total receivables, net | 505.81M | 1.11B | 893.61M | 476.31M | 728.39M |
| Accounts receivable - trade, net | 425.12M | 1.11B | 885.68M | 457.27M | 721.22M |
| Other receivables | 80.69M | 7.31M | 7.93M | 19.04M | 7.17M |
| Total inventory | 140.82M | 224.79M | 170.60M | 101.70M | 43.77M |
| Other current assets, total | 21.48M | 21.34M | 82.78M | 237.75M | 388.72M |
| Total non-current assets | 204.24M | 250.14M | 623.87M | 1.17B | 2.08B |
| Long term investments | 0 | 0 | 0 | 0 | 0 |
| Note receivable - long term | — | — | — | — | — |
| Investments in unconsolidated subsidiaries | 0 | 0 | — | 0 | 0 |
| Other investments | 0 | 0 | 0 | 0 | 0 |
| Net property/plant/equipment | 198.28M | 244.05M | 611.52M | 1.14B | 2.05B |
| Gross property/plant/equipment | 248.05M | 314.01M | 786.44M | 1.33B | 2.26B |
| Deferred tax assets | — | — | — | — | — |
| Net intangible assets | 0 | 0 | 0 | 0 | 1.08M |
| Goodwill, net | 0 | 0 | 0 | 0 | 0 |
| Other intangibles, net | 0 | 0 | 0 | 0 | 1.08M |
| Other long term assets, total | 5.96M | 6.09M | 12.35M | 34.40M | 35.72M |
| Short term debt | 2.72M | 14.59M | 1.75M | 16.18M | 170.87M |
| Current portion of LT debt and capital leases | 1.95M | 1.78M | 1.75M | 2.31M | 2.31M |
| Short term debt excl. current portion of LT debt | 770.00K | 12.81M | 0 | 13.88M | 168.56M |
| Accounts payable | 122.92M | 464.37M | 472.96M | 259.27M | 407.16M |
| Income tax payable | 22.21M | 0 | — | — | — |
| Long term debt | 3.32M | 596.67M | 600.43M | 750.90M | 1.05B |
| Long term debt excl. lease liabilities | 3.32M | 596.67M | 600.43M | 750.90M | 1.05B |
| Total equity | 885.82M | 714.60M | 1.00B | 2.37B | 2.34B |
| Shareholders' equity | 885.82M | 714.60M | 1.00B | 2.37B | 2.34B |
| Common equity, total | 885.82M | 714.60M | 1.00B | 2.37B | 2.34B |
| Other common equity | 0 | 326.19M | 163.39M | 0 | -194.00K |
| Total debt | 6.04M | 611.26M | 602.18M | 767.08M | 1.22B |
| Net debt | -183.33M | 405.93M | 248.58M | -671.15M | 456.95M |
| Change in accounts receivable | -207.01M | -682.72M | 215.07M | 428.41M | -272.74M |
| Change in taxes payable | — | — | — | — | — |
| Change in accounts payable | 14.43M | 353.35M | 80.24M | -213.69M | 147.89M |
| Change in other assets/liabilities | -41.98M | 144.26M | -71.34M | -248.69M | 27.05M |
| Sale of fixed assets & businesses | 0 | 400.00K | 0 | 0 | 557.00K |
| Purchase/sale of investments, net | -150.00M | -54.02M | -136.97M | -980.07M | 610.30M |
| Sale/maturity of investments | 0 | 0 | 199.20M | 0 | 610.30M |
| Purchase of investments | -150.00M | -54.02M | -336.17M | -980.07M | 0 |
| Other investing cash flow items, total | 0 | 0 | 0 | 0 | 0 |
| Issuance/retirement of debt, net | 130.29M | -418.80M | -9.09M | 166.50M | 449.79M |
| Issuance/retirement of long term debt | — | — | 0 | 152.63M | 296.86M |
| Issuance/retirement of short term debt | -1.85M | 1.92M | -9.09M | 13.88M | 152.93M |
| Issuance/retirement of other debt | 132.14M | -420.72M | — | — | — |
| Total cash dividends paid | 0 | 0 | 0 | 0 | 0 |
| Other financing cash flow items, total | 0 | 0 | 0 | 0 | 0 |
